Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Schmid, P; Kühnhardt, D; Kiewe, P; Lehenbauer-Dehm, S; Schippinger, W; Greil, R; Lange, W; Preiss, J; Niederle, N; Brossart, P; Freier, W; Kümmel, S; Van de Velde, H; Regierer, A; Possinger, K.
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Ann Oncol. 2008; 19(5):871-876
Doi: 10.1093/annonc/mdm569
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Schippinger Walter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Proteasome inhibitors are a novel class of compounds entering clinical trials as a method to increase tumour sensitivity to standard chemotherapy. This phase I/II trial was carried out to evaluate the combination of capecitabine and the proteasome inhibitor bortezomib in anthracycline and/or taxane-pretreated patients with metastatic breast cancer. PATIENTS AND METHODS: A total of 35 patients were treated with bortezomib (1.0-1.3 mg/m(2) on days 1, 4, 8 and 11) and capecitabine (1500-2500 mg/m(2) on days 1-14) in 3-week intervals for up to eight cycles. RESULTS: The maximum tolerated doses (MTDs) were bortezomib 1.3 mg/m(2) and capecitabine 2500 mg/m(2). The treatment was generally well tolerated and associated with toxic effects that were consistent with the known side-effects of the individual agents. The intent-to-treat overall response rate was 15% and an additional 27% of patients had stable disease (SD). In the 20 patients treated at the MTD, the response rate was 15% and 40% had SD. Median time to progression and overall survival were 3.5 months [95% confidence interval (CI) 1.9-4.4] and 7.5 months (95% CI 5.6-14.6), respectively. Median duration of response was 4.4 months. CONCLUSION: The combination of bortezomib and capecitabine is well tolerated and has moderate antitumour activity in heavily pretreated patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Anthracyclines - administration and dosage
- Antineoplastic Combined Chemotherapy Protocols - adverse effects
- Boronic Acids - administration and dosage
- Breast Neoplasms - drug therapy
- Carcinoma - drug therapy
- Deoxycytidine - administration and dosage
- Disease Progression -
- Drug Resistance, Neoplasm -
- Female -
- Fluorouracil - administration and dosage
- Hematologic Diseases - chemically induced
- Humans -
- Maximum Tolerated Dose -
- Peripheral Nervous System Diseases - chemically induced
- Pyrazines - administration and dosage
- Salvage Therapy -
- Survival Analysis -
- Taxoids - administration and dosage
- Treatment Outcome -
- Find related publications in this database (Keywords)
- bortezomib
- capecitabine
- chemotherapy
- metastatic breast cancer
- phase I study
- proteasome
- inhibition